Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. SG11201500998Q - METHODS OF TREATING CANCER USING 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE

Office Singapour
Numéro de la demande 11201500998Q
Date de la demande 08.08.2013
Numéro de publication 11201500998Q
Date de publication 29.04.2015
Type de publication A1
CIB
A61K 31/5377
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
31Préparations médicinales contenant des ingrédients actifs organiques 
33Composés hétérocycliques
395ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines
535ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p.ex. 1,2-oxazines
53751,4-Oxazines, p.ex. morpholine
5377non condensées et contenant d'autres hétérocycles, p.ex. timolol
G01N 33/50
GPHYSIQUE
01MÉTROLOGIE; TESTS
NRECHERCHE OU ANALYSE DES MATÉRIAUX PAR DÉTERMINATION DE LEURS PROPRIÉTÉS CHIMIQUES OU PHYSIQUES
33Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes G01N1/-G01N31/146
48Matériau biologique, p.ex. sang, urine; Hémocytomètres
50Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
A61P 35/00
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
PACTIVITÉ THÉRAPEUTIQUE SPÉCIFIQUE DE COMPOSÉS CHIMIQUES OU DE PRÉPARATIONS MÉDICINALES
35Agents anticancéreux
CPC
A61K 31/5377
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
A61K 9/0053
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0053Mouth and digestive tract, i.e. intraoral and peroral administration
Déposants CELGENE CORPORATION
Inventeurs SCHAFER, Peter, H.
GANDHI, Anita
Données relatives à la priorité 61/681,447 09.08.2012 US
61/722,727 05.11.2012 US
Titre
(EN) METHODS OF TREATING CANCER USING 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE
Abrégé
(EN)
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 February 2014 (13.02.2014) WIPOIPCT (10) International Publication Number WO 2014/025960 A1 (51) International Patent Classification: A61K31/5377 (2006.01) A61P 35/00 (2006.01) G01N33/50 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/054055 8 August 2013 (08.08.2013) English English US US (30) Priority Data: 61/681,447 9 August 2012 (09.08.2012) 61/722,727 5 November 2012 (05.11.2012) (71) Applicant: CELGENE CORPORATION [US/US]; 86 Morris Avenue, Summit, NJ 07901 (US). (72) Inventors: SCHAFER, Peter, H.; 126 John E. Busch Av­ enue, Somerset, NJ 08873 (US). GANDHI, Anita; 37 Stirling Road, Bernardsville, NJ 07924 (US). (74) Agents: CHOI, Hoon et al.; Jones Day, 222 East 41st Street, New York, NY 10017-6702 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: METHODS OF TREATING CANCER USING 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-l-OXOISOIN- DOLIN-2-YL)PIPERIDINE-2,6-DIONE Effect on Compound I on Cytokine and Chemokine Production in Anti-CD3-stimulated Human T Cells-Absolute Amount Produced Effect on Compound I on Cytokine and Chemokine Production in Anti—C03—stimulated Human T Cells-Absolute Amount Produced - IFN-gamma - RANTES - IL—13 - IL—10 Concentration of Compound I ()iU) Concentration of Compound I (/iM) O o\ CJ o o CJ O Concentration of Compound I (jtiM) FIG. 1 - IL-3 - IL-5 - IL-17A Concentration of Compound I (fiVi) FIG. 1 (Cont'd) (57) Abstract: Provided herein are methods of treating, preventing and/or managing cancers, which comprise administering to a pa­ tient 3-(4-((4-(morpholinomethyl)benzyl)oxy)-l-oxoisoindolin-2-yl) piperidine-2,6-dione, or an enantiomer or a mixture of enan- tiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, polymorph thereof. or